FDA Clears GenePOC Group B Streptococcus Assay, MDx Platform

Jun 01, 2017

|

NEW YORK (GenomeWeb) – GenePOC today said that it has received FDA clearance to market its molecular assay for detecting Group B streptococcus and its Revogene molecular diagnostics instrument in the US.

The test and instrument was launched in Europe earlier in the year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

FDA Clears GenePOC Group B Streptococcus Assay, MDx Platform

To read the full story....

Breaking News

FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

German Stores to Begin Selling COVID-19 Rapid Antigen Tests for Home Use

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

DermTech Q4 Revenues Up 31 Percent

Featured White Papers

What's Popular?

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Dx Developers Hedge on SARS-Cov-2 Rapid Antigen Tests, Citing Conflicting FDA Messages

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test

Abbott SARS-CoV-2 IgG Antibody Test Receives Emergency Use Authorization from FDA

Sponsorships